Variable | Included studies | Positive cases | Total cases | Rate (%) (95% CI) |
---|---|---|---|---|
Total IPD | 16 | 1218 | 2146 | 10.0 (5.0–14.9) |
1 | 3 | 9 | 155 | 4.9 (1.5–8.3) |
3 | 1 | 4 | 56 | 7.1 (0.4–13.9) |
4 | 1 | 1 | 61 | 1.6 (1.5–4.8) |
5 | 6 | 13 | 368 | 2.6 (1.0–4.2) |
6A | 1 | 1 | 21 | 4.8 (4.3–13.9) |
6B | 3 | 96 | 1006 | 8.0 (5.2–10.8) |
7F | 3 | 8 | 173 | 4.5 (1.4–7.6) |
9 V | 7 | 23 | 357 | 5.7 (3.3–8.1) |
14 | 11 | 140 | 796 | 16.5 (12.8–20.1) |
18C | 15 | 5 | 171 | 2.9 (0.45.4) |
19A | 15 | 241 | 1197 | 21.2 (16.4–26.1) |
19F | 13 | 419 | 1197 | 27.7 (17.7–37.6) |
23F | 14 | 94 | 1062 | 7.3 (5.2–9.5) |
PCV7 serotype coverage | 14 | 752 | 1197 | 60.8 (52.2–69.4) |
PCV10 serotype coverage | 14 | 784 | 1197 | 65.1 (57.7–72.4) |
PCV13 serotype coverage | 14 | 1030 | 1197 | 90.0 (87.1–92.8) |